Skip to content
DraconiticResearch
Search Sources API
182,544 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BY-NC-NDLeukemia research reports

The prognostic value of KRAS, NRAS, and BRAF genes mutations in patients with newly diagnosed multiple myeloma.

  • Phuong Thao Pham1,2
  • Hoang Viet Nguyen3
  • Minh Phuong Vu1,2
  1. 1Department of Hematology, Hanoi Medical University, Hanoi, 11521, Vietnam.
  2. 2Hematology and Blood Transfusion Center, Bach Mai Hospital, Hanoi, 11519, Vietnam.
  3. 3Faculty of Medical Technology, Hanoi Medical University, Hanoi, 11521, Vietnam.
Read full textPDFDOICite

Abstract

Background

KRAS, NRAS, and BRAF (RAS/RAF) genes mutations play a role in the pathogenesis of multiple myeloma (MM). We conducted this study to investigate whether RAS/RAF genes mutations have a prognostic value in patients with MM.Material and methods

117 newly diagnosed MM patients underwent the FISH technique to detect high-risk cytogenetic abnormalities and next-generation sequencing (NGS) to detect KRAS, NRAS, BRAF and TP53 mutations.Results

In the study patient group, patients with the KRAS mutation had significantly longer OS and PFS compared to those with the TP53 mutation; patients with the BRAF mutation had significantly longer OS compared to those with the TP53 mutation. In the patient without high-risk cytogenetics based on FISH, patients with the KRAS mutation had significantly longer OS and PFS compared to those with the TP53 mutation. Conversely, in the patients with high-risk cytogenetics based on FISH, no difference in survival time has been observed among patient groups harboring different gene mutations.Conclusions

RAS/RAF gene mutations may have important prognostic implications for MM but should be considered in conjunction with other abnormalities, such as chromosomal abnormalities and TP53 mutations.

Related

  1. Prognostic Impact of EASIX According to the Timing of Assessment in Newly Diagnosed Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
    Diana Fortoeș, Ion Antohe, Vlad-Andrei Cianga +10
    Medical sciences (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Ki-67 Proliferation Index Improves the Prognostic Stratification Accuracy of International Staging System in Newly Diagnosed Multiple Myeloma
    Xiaoqi Qin, Jingliang Zhao, Qirui Bai +5
    CancersPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMC
  3. Stem cell mobilization with G-CSF and on-demand plerixafor in newly diagnosed multiple myeloma patients treated with daratumumab: a single-center experience
    Barbara Skopec, Luka Cemazar, Matevz Skerget
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyCrossref
  4. Exploring Cross-Sectional and Longitudinal Associations Among DNA Methylation, Prognostic Proteins, and Symptoms in Patients Prescribed Oral Anticancer Medications for Multiple Myeloma.
    Abigail Lustyik, Yvette P Conley, Catherine M Bender +5
    Biological research for nursingPeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
  5. DARATUMUMAB PLUS BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: FINAL ANALYSIS OF TRANSPLANT-INELIGIBLE PATIENTS IN THE PHASE 3 CEPHEUS STUDY
    Saad Z USMANI, Thierry FACON, Vania HUNGRIA +17
    Hematology, Transfusion and Cell TherapyPeer-reviewedCC BYFull textEndocrinology & metabolismDOAJ

Cite

BibTeXRIS
BibTeX
@article{pham2026prognostic,
  title = {{The prognostic value of KRAS, NRAS, and BRAF genes mutations in patients with newly diagnosed multiple myeloma.}},
  author = {Phuong Thao Pham and Hoang Viet Nguyen and Minh Phuong Vu},
  journal = {Leukemia research reports},
  year = {2026},
  month = oct,
  doi = {10.1016/j.lrr.2026.100615},
  url = {https://europepmc.org/article/MED/42903670},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - The prognostic value of KRAS, NRAS, and BRAF genes mutations in patients with newly diagnosed multiple myeloma.
AU  - Phuong Thao Pham
AU  - Hoang Viet Nguyen
AU  - Minh Phuong Vu
PY  - 2026
DA  - 2026/10/08
JO  - Leukemia research reports
DO  - 10.1016/j.lrr.2026.100615
UR  - https://europepmc.org/article/MED/42903670
AB  - Background  KRAS, NRAS, and BRAF (RAS/RAF) genes mutations play a role in the pathogenesis of multiple myeloma (MM). We conducted this study to investigate whether RAS/RAF genes mutations have a prognostic value in patients with MM.Material and methods  117 newly diagnosed MM patients underwent the FISH technique to detect high-risk cytogenetic abnormalities and next-generation sequencing (NGS) to detect KRAS, NRAS, BRAF and TP53 mutations.Results  In the study patient group, patients with the KRAS mutation had significantly longer OS and PFS compared to those with the TP53 mutation; patients with the BRAF mutation had significantly longer OS compared to those with the TP53 mutation. In the patient without high-risk cytogenetics based on FISH, patients with the KRAS mutation had significantly longer OS and PFS compared to those with the TP53 mutation. Conversely, in the patients with high-risk cytogenetics based on FISH, no difference in survival time has been observed among patient groups harboring different gene mutations.Conclusions  RAS/RAF gene mutations may have important prognostic implications for MM but should be considered in conjunction with other abnormalities, such as chromosomal abnormalities and TP53 mutations.
SN  - 2213-0489
ER  -